OBI Pharma, Inc.
TWO: 4174.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Heidi Wang
- Employees
- 260
- Headquarters
- Taipei, Taiwan
- IPO year
- 2012
- Market cap
- NT$4.5B
- Website
- https://www.obipharma.com
Loading 4174…
Loading profile data…Frequently asked questions about 4174
What does OBI Pharma, Inc. (4174.TWO) do?
OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer...
Where does 4174.TWO trade?
OBI Pharma, Inc. (4174.TWO) trades on the Taipei Exchange.
What sector is 4174.TWO in?
OBI Pharma, Inc. (4174.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of OBI Pharma, Inc.?
Heidi Wang is the chief executive officer of OBI Pharma, Inc. (4174.TWO).
Where is OBI Pharma, Inc. headquartered?
OBI Pharma, Inc. is headquartered in Taiwan.
Does 4174.TWO pay a dividend?
OBI Pharma, Inc. (4174.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4174.TWO go public?
OBI Pharma, Inc. (4174.TWO) completed its initial public offering in 2012.